Navigation Links
Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
Date:6/8/2009

al," said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "Later this year we will complete Phase 1 testing of the IV dosage form of torezolid and plan to merge the oral and IV programs in Phase 3 testing early next year. Our aim is to make torezolid available to physicians and patients as soon as possible to address the growing unmet medical need for an effective and well tolerated new IV and oral treatment for drug-resistant infections."

About Torezolid (TR-701)

Torezolid is a second-generation IV/oral antibacterial drug in the oxazolidinone class. It is significantly differentiated from Zyvox(R) (linezolid), the only marketed drug in this class. Advantages of torezolid over linezolid include:

  • 4-8 fold greater potency than linezolid in vitro and in vivo
  • In vivo bactericidal activity
  • Activity against all clinically important, gram-positive, drug-resistant strains including those resistant to linezolid
  • Activity against clinically important atypical and gram-negative pathogens (Legionella, Chlamydia, Neisseria)
  • 16x lower rate of resistance development in MRSA
  • Once-daily and shorter course of therapy to promote better treatment compliance
  • Broader safety window enabling potential longer course of therapy
  • Possibility for expanded indications including bacteremia, severe CAP and osteomyelitis
  • Lower potential for drug-drug interactions including those with dietary tyramine, SSRIs and vasoconstrictors

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity agai
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
2. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
3. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
4. Trius Doses First Patient in Antibacterial Phase 2 Trial
5. PacificGMP Completes GMP Product Fill for Trius Therapeutics
6. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
7. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
8. Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
9. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
10. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
11. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... NEW YORK , Oct. 1, 2014 ... market and is marked by the ,Threat of Obsolescence, ... users changes very rapidly. Pharmaceutical and biotechnology companies as ... on using high content screening as a powerful research ... market is the fastest-growing segment in the high content ...
(Date:10/1/2014)... Ohio , Oct. 1, 2014 /PRNewswire/ ... shareholders is now available. Interested parties can learn ... how Cardinal Health is supporting the health ... http://cardinalhealth.com/annualreport . Photo- ... to summary financials and the chief executive ...
(Date:10/1/2014)... NOTTINGHAM, England , Oct. 1, 2014 /PRNewswire/ ... announced that its subsidiary, Molecular Profiles Ltd., is set ... the annual CPhI/ICSE Worldwide event in Paris ... with the rapid development of both standard and complex ... platform, which incorporates the company,s existing formulation and analytical ...
Breaking Medicine Technology:High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 2High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 3Cardinal Health 2014 Digital Report to Shareholders Now Available 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 3
... TEL AVIV, Israel, May 5, 2011 InspireMD, Inc. (OTC ... MGuard™ mesh protective stent system, announced today that it has ... the Over-the-Counter Bulletin Board (OTCBB) under the symbol "NSPR". ... $9.7 million PIPE offering in which (i) it raised approximately ...
... Today, the Consumer Healthcare Products Association (CHPA), ... pediatric acetaminophen medicines, announces plans to convert these ... transition is taking place, starting in mid-2011, parents ... products with confidence as current labeling and dosing ...
Cached Medicine Technology:InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR" 2InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR" 3InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR" 4InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR" 5OTC Industry Announces Voluntary Transition to One Concentration of Single-Ingredient Pediatric Liquid Acetaminophen Medicines 2
(Date:10/2/2014)... (PRWEB) October 02, 2014 BamboofloorChina.com is ... its products have won great appreciation from the global ... is working hard to make more excellent items. All ... ready to help all clients. , The company ... panels to its website. Furthermore, the company’s marketing ...
(Date:10/2/2014)... News) -- Scientists have pinpointed a molecule that may ... The researchers say this finding could offer a ... these attacks. Most asthma attacks (80 percent to ... airways, according to the British researchers. Most of these ... common cold. The researchers found that a specific ...
(Date:10/2/2014)... Reinberg HealthDay Reporter WEDNESDAY, ... major highway may raise your risk for high blood pressure, ... women, those who lived within 109 yards of a busy ... blood pressure than women living at least half a mile ... highlight the importance of our physical environment on our health ...
(Date:10/2/2014)... Dennis Thompson ... News) -- Hospitals that pull out all the stops ... at saving lives, but the cost of such heroism ... hospitals are about 5 percent better at saving elderly ... hospitals that operate with less intensity, said senior author ...
(Date:10/1/2014)... of Adelaide have developed a model that could help ... from treatment - from their very first psychotic episode. ... factors, including clinical symptoms, cognitive abilities, MRI scans of ... , Speaking in the lead up to World Mental ... Psychiatry , Professor Bernhard Baune , says the ...
Breaking Medicine News(10 mins):Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:New Clues to How Colds Can Spur Asthma Attacks 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Predicting the future course of psychotic illness 2
... ... service available around the globe and simple to use, with more than ... only registration, upload of funds and you are ready to call your ... to establish the phone call. SOS Talk is fully automated, serving not ...
... ... media issues as the space rapidly evolves. Smart companies are learning to engage their audiences ... (PRWEB) ... valuable marketing & research tools available. Big pharma companies looking for an information edge are ...
... ... They don,t need the pretty bottles or sweet aroma of fragrant lotions and ... is tailored specifically to a man,s needs without added synthetic ingredients that may ... Adam uses the purity of nature to enhance the skin,s surface and makes ...
... ... fear out of processing grief after an abortion. C.P.R. Choice Processing and Resolution ... might feel after their voluntary pregnancy termination or abortion . Women caught off ... www.sadafterabortion.com for reassurance and some free resources. , ...
... ... they have recently been awarded an agreement with Premier Partners L.P., the group purchasing unit ... and serves 2,300 hospitals and more than 66,000 other healthcare sites representing over $33 billion ... Jackson, ...
... Cosmetic ... new buy back plan. , ... (PRWEB) – CosmeticLaserWorld.com ( www.cosmeticlaserworld.com ), a market leader in cost-effective cosmetic ... equipment from the reseller. Under an Investment Protection Plan, the company will buy back ...
Cached Medicine News:Health News:SOS Talk a New Way of Telephone Interpreting Serving the Globe, No Reservation or Start-Up Cost, Just Pay as You Go 2Health News:Pharma Companies Head Toward The Social Media Dialogue 2Health News:Garden of Eve Launches a Father's Day Tribute for Men Who Want to Look Well-groomed with Little Fuss 2Health News:Garden of Eve Launches a Father's Day Tribute for Men Who Want to Look Well-groomed with Little Fuss 3Health News:Garden of Eve Launches a Father's Day Tribute for Men Who Want to Look Well-groomed with Little Fuss 4Health News:New Website and Self-Help Book Validate Women Experiencing Grief After an Abortion 2Health News:New Website and Self-Help Book Validate Women Experiencing Grief After an Abortion 3Health News:New Website and Self-Help Book Validate Women Experiencing Grief After an Abortion 4Health News:Midbrook Medical Announces Agreement with Premier Partners L.P. 2Health News:Midbrook Medical Announces Agreement with Premier Partners L.P. 3Health News:CosmeticLaserWorld.com Gives Buyers Peace of Mind Through Industry-Leading Investment Protection Plan 2
Fully automated immunochemiluminometric assay for the rapid intraoperative,measurement of Intact PTH 1-84 using human serum or EDTA plasma....
... The innovative PoleStar N20, exclusively distributed ... intra-operative MRI. Combining intra-operative imaging ... registration-free system, PoleStar N20 is one ... available today. , , Exceptional image ...
... nm and 940 nm) laser system is ... solid-state laser quickly and effectively treats vascular ... offers the clinical versatility to precisely target ... vessels in a convenient, affordable package. , ...
Microwell IRMA for the detection of Intact PTH...
Medicine Products: